Introduction
============

Red blood cell (RBC) transfusion is a life-saving procedure whose primary objective is to sustain tissue and organ oxygenation in patients with massive bleeding or acute anemia. Packed red blood cell (PRBC) donations for transfusion are routinely stored for up to 35 or 42 days, depending on the preservation solution. This time limit has been determined mainly by the recovery and the lifespan of the RBCs in the circulation of recipients.

During cold-storage, PRBCs undergo slow detrimental changes that are collectively termed storage lesion. Oxidative-stress and defective adenosine triphosphate (ATP) metabolism are the main driving forces in the development of PRBC lesion. Storage-related processes lead to significant metabolic and structural changes of erythrocytes that include global biochemical and biophysical alteration, remodeling of the cell membrane and cytoplasm composition ([@B46]; [@B68]).

The most studied changes include: (ATP) and 2,3-bisphosphoglycerate (2.3-DPG) depletion ([@B46]), loss of cellular antioxidant capability ([@B75]; [@B33]), changes in K^+^ and Na^+^ concentration ([@B69]; [@B22]), loss of membrane' and skeleton proteins ([@B21]; [@B70]), loss of membrane lipids and changes in their in/out distribution, vesicle generation ([@B16], [@B15]), oxidation and remodeling of skeleton proteins ([@B94]), clustering of band 3 proteins ([@B71]; [@B4]), alteration of nitric oxide signaling ([@B2]; [@B58]), decrease in antioxidant activity ([@B34]; [@B35]; [@B92]) etc.

A number of these changes are interrelated and initiate a cascade of biochemical and structural changes which in turn lead to impairment in RBC functionality, specifically -- alteration in the biophysical/mechanical properties of cells.

Each of the reported storage-induced alterations in PRBC properties occurs on its specific time-scale ([@B27]; [@B10]; [@B28]; [@B77]; [@B23]; [@B41]; [@B80]; [@B53]; [@B5]). Some of these changes take place at an early stage of storage (during the first 7 days), while others occur later. [@B73] have extensively discussed this issue, distinguishing between the separate phases of PRBCs lesion development and providing a detailed scheme of the various changes on a time-scale. Different stages of cell aging are also reported by [@B66], [@B67]) and [@B41].

When a patient is being transfused with a PRBCs unit, cells with a specific set of features are administered into his bloodstream. Senescent transfused cells, with a high degree of damage, are removed from the bloodstream shortly following the transfusion ([@B49]). Furthermore, we have recently demonstrated a dependence of transfusion-induced hemoglobin increment (determined upon completion of the transfusion) on the percentage of low-deformable cells in the population of the transfused RBCs (TRBCs) unit ([@B7]). We suggested that during the transfusion the relatively rigid cells in the TRBCs population (composing dozens of percentages) are immediately removed itself. This suggestion is in accord with previous reports indicating that the clearance of TRBCs starts directly with the administration of cells into the bloodstream ([@B61]; [@B14]).

Rigid and fragile RBC are subject to facilitated removal from circulation within the first hours after transfusion, due to shear forces operating in the bloodstream ([@B65]). Thus, [@B61] concluded that significant portion of the TRBCs that do not survive the first 24 h are removed from the circulation within the first few hours after transfusion.

Following removal of the extremely damaged cells, most of the TRBCs \[in the range of 75% ([@B61])\] remain in the bloodstream of the recipient in an environment substantially different from the one in which they were stored. As a result, the remaining TRBCs can partially restore their functionality and to remain in the recipient's blood for a more extended period. The average lifespan of transfused RBCs is about 50--60 days, but it can be significantly shorter in the presence of factors reducing their survival ([@B59]).

Accordingly, an assessment of reversibility of the cold-storage lesion is a critical issue in the field of RBCs storage and transfusion as the ability of transfused RBCs to restore their properties following transfusion. This ability largely determines TRBCs behavior in the bloodstream of the recipient.

In the present review, we discuss publications that examined RBC lesions induced by the cold-storage, aiming to offer a better understanding of the time frame in which these lesions occur, with particular emphasis on the question of their reversibility. Also, we propose an approach for assessing the potential for reversibility of the damage to specific properties of PRBCs.

Post-Transfusion Behavior of RBCs
=================================

Of all the properties of TRBCs, the ability to restore of ATP and 2,3-DPG levels is most extensively discussed in the literature. Since some physiological factors can modify the time course of the post-transfusion restoration, the reported time needed for full recovery varies widely from several hours to several days ([@B90]; [@B12]; [@B89]; [@B36]; [@B45]). The ATP level in TRBCs rapidly increases in the recipient's bloodstream ([@B89]; [@B45]). [@B89] suggested that this effect is associated with a rapid decrease in the donor cell Na^+^ content during the 24 h post-transfusion period. In parallel, TRBC cellular K^+^ content is gradually increased, with the rate of this increase being related to the increasing level of intracellular 2,3-DPG ([@B89]).

[@B45] measured the levels of 2,3-DPG and ATP in transfused cells for 1 week following the transfusion. The authors demonstrated that an average of 95% of the recipients' pre-transfusion 2,3-DPG level was reached by 72 h, while ATP level in started increasing 1 h after transfusion ([@B45]). [@B26] have reported that the repairing of Na^+^/K^+^ pump activity occurred during 1 to 4 days.

In contrast to the data presented so far, some publications ([@B38]; [@B19], [@B18]) have reported a deterioration in the TRBCs properties following their interaction with human plasma. Thus, [@B19], [@B18]) demonstrated that an *ex vivo* incubation of PRBCs with the plasma of healthy subjects ([@B19], [@B18]), patients with sepsis ([@B18]) and sickle anemia patients ([@B19]) induced alterations in the phosphatidylserine (PS) externalization and a decrease in the average cell size.

[@B38] measured deformability of RBCs from post-surgery patients prior to and following a moderate (≥five units) or a minimal (≤four units) PRBC transfusion. They demonstrated that deformability of the patients' RBCs has decreased following transfusion as compared to pre-transfusion cells, and this abnormality was not reversed and even got worse during the subsequent 3 days.

What Lesion Is Reversible?
==========================

Which are the properties of the stored PRBCs that we can expect to be corrected, and which ones are not? This question is extensively discussed in the literature ([@B11]; [@B61]; [@B26]; [@B73]). For example, D'Alessandro et al. suggest that the reversibility of these changes is inversely proportional to the duration of storage ([@B26]). Prudent et al. takes a similar position ([@B73]), with the authors concluding that an "early" lesion (i.e., one that occurs following first 2 weeks of storage) is reversible, while a "late" lesion (4 weeks and more) is not. This suggestion is supported by *in vivo* studies of TRBCs performed by [@B11] and [@B61], who conclude that RBC storage is associated with irreversible damage that increases with storage duration.

Do Any Irreversible Changes Occur in the Early Stages of Storage?
=================================================================

During the first week of storage, RBC lesion is characterized by the formation of micro-defects in the RBC membrane and a decrease in the membrane roughness, as assessed by atomic force microscopy ([@B43]; [@B72]; [@B53]; [@B1]). For example, [@B53] demonstrated that by days 9 to 12 topological defects in the form of "domains" appear on the membrane surface. These defects initially appear as grain-like structures ("grains") of up to 200 nm (on days 16--23), and later merge to form large defects, 400--1000 nm. This observation conforms with that of [@B43] and [@B72], who used atomic force microscopy to examine storage-induced structural and metabolic changes in PRBCs. The authors demonstrated that the RBC roughness might be restored to the initial value only in samples stored for up to 4--5 days, whereas after the eighth day of storage the rejuvenation procedure appears to be inefficient. [@B42], [@B43]) concluded that some changes, localized on the membrane surface, appear when the ATP synthesis capacity declines to apparently sub-viable levels and the membrane-skeleton is permanently damaged ([@B72]).

Moreover, irreversible reduction in surface charge ([@B44]; [@B82]; [@B37]) has been observed under different conditions of RBC *in vitro* aging. Specifically, [@B82] examined the effect of cold-storage of human RBCs (collected into CPD-SAGM, leukodepleted and unleukodepleted) on the ξ-potential of the cell membrane, and demonstrated that the ξ-potential of cells decreases during the first week of storage. The same authors ([@B82]) have also demonstrated that ξ-potential decay (30%) of RBC samples (leukodepleted and not) was more pronounced during the first week of storage, suggesting that this decay is caused by oxidative damage generated by the production of reactive oxygen species.

The authors suggest that the decrease in RBC deformability observed during cell aging (*in vivo*) ([@B48]) and cold storage ([@B82]) could arise from a reduction of their ξ-potential.

Moreover, a release of microvesicles from RBC membrane starts at the second week of cold-storage. These vesicles are characterized by a significant fraction of lipid raft proteins \[such as stomatin and flotillins ([@B79])\] as well as oxidized or reactive signaling components commonly associated with senescent RBCs. [@B54] demonstrated that the vesicular protein content progressively increased over time, with a twofold increase in PRBCs stored for 17 days as compared to those stored for 7 days.

The formation of microvesicles leads to a decrease in the content of membrane proteins ([@B79]; [@B93]; [@B23]) and a change in the composition of the cytoskeleton. Thus, [@B21] suggested that part of the membrane skeleton is lost together with components of the lipid bilayer in a balanced way.

[@B83] demonstrated that during cold-storage the protein components of RBC skeleton are partially decomposed. The thickness of the cell membrane is reduced during storage and, specifically, shows a sharp decrease from the 6^th^ to the 14^th^ day of cold-storage.

Mechanism of vesiculation is discussed in detail in numerous publications ([@B25]; [@B3]; [@B21]). Nonetheless, the selective sorting of specific membrane components into microvesicles remains to be understood. In any case, regardless of the mechanism, the formation of vesicles leads to irreversible changes in the composition and structure of the membrane. Specifically, it induces a decrease in the area-volume ratio, which affects the cells' shape, their mechanical properties ([@B86]) and survival in the bloodstream ([@B29]).

Thus, some basic cells properties are irreversibly altered during the first to third week of storage. These changes necessarily produce alterations in the functionality of the transfused erythrocytes, some of which cannot be fully reversed following transfusion ([@B8]).

Post-Storage Rejuvenation Treatment *In Vitro*
==============================================

One of the possible procedures proposed for the reversal of storage-induced damage is post-storage rejuvenation treatment, which consists of supplementing PRBC units with rejuvenation solution before their transfusion ([@B51]; [@B60]; [@B91]; [@B74]). A commercially available rejuvenation solution is produced under trademark Rejuvesol and consists of sodium pyruvate, inosine, adenine, and sodium phosphate. The FDA approves this solution and, although rarely applied in clinical blood banking, is widely used in research for restoring cellular ATP and 2,3-DPG levels ([@B27]; [@B96]; [@B64]). Of course, the research results should be interpreted with caution as an *in vitro* method with significant limitations for clinical interpretation.

The rejuvenation procedure can be carried out at 37°C ("warm") and 4°C ("cold"), with the "warm" type being more extensively studied than the cold one. Still, a comparison of the results reported by different authors ([@B27]; [@B52]; [@B87]; [@B8]; [@B55]) leads to the conclusion that rejuvenation is more effective when performed at 37°C. In the following section, we will only consider results obtained with a warm treatment, which is consistent with the objective of the present review.

Indeed, during previous attempts to attenuate the impairment of PRBCs functionality caused by cold-storage, it was shown that rejuvenation treatment could restore intra-cellular ATP and 2,3-DPG levels and thus reverse a storage-induced alteration to various properties of cells ([@B32]; [@B52]; [@B8]). Specifically, rejuvenation leads to repairing of PRBCs morphology ([@B88]) and mechanical properties: deformability ([@B6]; [@B27]; [@B8]) and fragility ([@B30]; [@B40]; [@B8]), although, as could be expected, this positive effect decreases with an increasing storage duration ([@B27]; [@B64]).

Importantly, the effect of rejuvenation on stored PRBCs is not limited to the restoration of intracellular levels of ATP and 2,3-DPG: it was shown that treatment of stored cells by Rejuvesol had induced significant metabolic reprogramming, including reactivation of energy-generating and antioxidant pathways, and membrane lipid recycling ([@B24]).

Reversibility of PRBC Lesion *In Vitro*
=======================================

In this section, we will focus on the reversibility of specific functional properties of cells that determine their behavior after transfusion to the patient, especially -- PS externalization and mechanical properties of their membrane.

The regulated plasma/membrane PS asymmetry is critical to many biological processes ([@B17]; [@B56]; [@B62]; [@B31]). Thus, it has been shown that PRBCs storage initiates Ca^2+^ influx into cells with subsequent PS externalization and amplifies the susceptibility of TRBCs to eryptosis, the "suicidal" death ([@B57]). Furthermore, erythrocyte surface PS has been reported to activate coagulation and thus induce thrombosis ([@B20]; [@B81]; [@B39]).

PS externalization can be mediated by the decrease in the ATP level ([@B13]) and/or by activation of scramblase ([@B9]; [@B95]). Therefore, the storage-induced increase in intracellular \[Ca^2+^\] ([@B52]; [@B57]) may be sufficient to induce the observed elevation of PS-positive PRBCs via the activation of scramblase ([@B9]; [@B95]). Alternatively, [@B91] have reported that cold-storage did not activate scramblase (by Ca^2+^ influx), but rather inhibited flippase activity as a result of ATP depletion, which was subsequently reversed by the treatment with Rejuvesol ([@B27]; [@B96]; [@B64]). However, whatever the mechanism of action, since intracellular Ca^2+^ concentration is ATP dependent ([@B63]), the renewal of ATP content in PRBCs as a result of rejuvenation should lead to the restoring of phospholipids' asymmetry ([@B63]).

In agreement with this assumption, [@B52] have recently shown that the storage-induced alterations in PRBCs (elevation of \[Ca^2+^\], and PS externalization) are almost completely rectified by post-storage rejuvenation treatment, which caused a decrease in RBC adhesion to endothelial cells.

In discrepancy to this observation, in our publication ([@B8]) we demonstrated that treatment with the Rejuvesol causes only partial restoration of the cells' mechanical properties (deformability and fragility).

To explain the difference in rejuvenation efficiency reported by different groups, we assumed that it is related to the degree of dependency of the specific property on the intracellular ATP concentration.

Indeed, it is well-known that various RBC functions and properties are mainly, if not solely, determined by the cell ATP level. Thus, it is plausible to expect the rejuvenation to be more effective in restoring cell properties that are strongly ATP-dependent.

To assess rejuvenation effectiveness (i.e., the degree of reversibility) we have formulated ([@B8]) rejuvenation effectiveness index (REI), describing the percentage of storage-induced damage to a specific RBC property that is restored by treatment.

In our publication ([@B8]) we summarized previously obtained results regarding reversibility of PRBC lesion and had shown that treatment of PRBCs with Rejuvesol had restored all tested properties. However, the extent of improvement varied considerably between the different measures, leading us to suggest that the REI is higher for features that are more ATP-dependent. Thus, for intracellular Ca^2+^ content and the level of PS externalization, REI is nearly 70%, with full recovery of RBC adhesion. In contrast, the rejuvenation efficacy in repairing the PRBC mechanical properties (deformability and fragility), was only 50%.

Of particular interest are the findings previously presented by us ([@B8]), showing that the efficacy of rejuvenation in the reversal of storage-induced impairment in the RBC mechanical properties depends on the extent of damage -- thus, the higher the damage, the lesser the rejuvenation efficacy ([@B8]). Changes in RBC mechanical properties are often associated with irreversible structural alterations, such as changes in RBC surface-to-volume ratio due to vesiculation ([@B78]), or reduction in surface charge due to sialic acid degradation ([@B44]; [@B48]), which are not expected to be affected by restoring the ATP content of RBC. These changes in the RBC membrane structure have been reported to increase with storage duration ([@B82]), thereby explaining why the rejuvenation efficacy is inversely related to the extent of storage-induced damage to PRBCs mechanical properties.

Thus, the ability of PRBCs to reverse (wholly or partially) their deformability and intracellular \[2,3-DPG\] content can explain the results obtained by [@B74]. The authors tested human PRBCs in an isovolemic transfusion model in rats after hemodilution. The cells were derived from units of PRBCs and transfused to animals with or without rejuvenation treatment before transfusion. It was demonstrated ([@B74]) that the rejuvenation of cells can completely reverse the reduced oxygenation capacity of long-stored human PRBCs in hemodiluted rats before transfusion.

Limitations
===========

In presented mini-review, we discussed the reversibility of PRBC lesion induced by cold-storage. For this purpose, we reviewed different studies examining PRBC recovery under *in vivo, ex vivo*, and *in vitr*o conditions. However, it is necessary to take into account the difference between the potential recoverability of a cell's specific feature(s), and the possibility of its restoration after a PRBC transfusion to the patient.

Future Direction
================

As demonstrated above, the reversibility of the RBC lesion *in vitro* (by incubation with Rejuvesol) has been extensively discussed in the cited literature. Unfortunately, this issue has been poorly studied under *in vivo* conditions, despite its theoretical and practical significance in assessing the role that storage lesion plays in transfusion outcome. Currently, PRBC units are supplied for transfusion on the first-in-first-out (FIFO) basis, assuming that their functionality is equal for all units with equal pre-transfusion storage duration. Thus, a number of large-scale clinical trials, both published ([@B47]; [@B84]; [@B76]; [@B85]) and ongoing ([@B50]), have focused their attention on the conditions of storage (specifically -- on storage duration), and not on the properties of transfused RBCs and the reversibility of the storage lesion in the bloodstream. We believe that studying the PRBC lesion reversibility after transfusion should be the future direction of research on this subject, being of fundamental importance for assessing the survival of TRBCs in the bloodstream, and potentially leading to the improvement in the transfusion outcome.

Conclusion
==========

It is well-documented that the cold-storage of PRBC units is associated with a change in a wide range of RBCs properties, each of them taking place on its own specific timescale. Thus, even at an early stage of storage (the first or second week), irreversible changes in the properties of the cells can already occur.

Despite the fact that the behavior of TRBCs in the recipient's bloodstream is still insufficiently studied, it can be argued at this stage that transfused cells are capable of restoring the pre-storage levels of ATP and 2,3-DPG, with subsequent restoration of cell functionality. This assumption is confirmed by the results of *in vitro* experiments demonstrating significant restoration of various PRBC features following incubation with a rejuvenation solution, especially those with a more pronounced ATP-dependence. The extent of reversal is inversely proportional to the extent of damage, and some of the changes cannot be fully reversed.

We hope that this review may stimulate further research into the field of cold storage and rejuvenation discussed here, and thus aid in the formulation of a new paradigm for PRBCs units inventory management.
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